CCS
CORT icon

Crosspoint Capital Strategies’s Corcept Therapeutics CORT Stock Holding History

Crosspoint Capital Strategies’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-631
Closed -$11.4K – 23
2017
Q4 		$11.4K Buy
631
+166
+36% +$3.01K 0.01% 79
2017
Q3 		$9K Buy
+465
New +$6.93K 0.01% 73
2017
Q2 		– Sell
-792
Closed -$9K – 147
2017
Q1 		$9K Hold
792
– – 0.01% 67
2016
Q4 		$6K Buy
+792
New +$6.21K 0.01% 99

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Crosspoint Capital Strategies's CORT Position: Q1 2018 in Review

Crosspoint Capital Strategies sold out of Corcept Therapeutics (CORT) in Q1 2018, closing a stake of 631 shares — an estimated $11.4K sold.

Crosspoint Capital Strategies first reported a position in CORT in Q4 2016 and held it in 4 quarters. The position peaked at $11.4K in Q4 2017. 212 funds tracked by Wall St. Rank hold CORT as of Q1 2018.

  • Crosspoint Capital Strategies reported no remaining Corcept Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 631 Corcept Therapeutics shares in Q1 2018, an estimated $11.4K.
  • Crosspoint Capital Strategies first reported a position in Corcept Therapeutics in Q4 2016 and held it in 4 quarters.
  • Crosspoint Capital Strategies's Corcept Therapeutics position peaked at $11.4K in Q4 2017.
  • 212 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2018.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2018, filed 14 May 2018.